Regeneron’s Pasatru Approved for Adult FOP, Second Disease-Modifying Therapy
The FDA approved Regeneron’s Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). The fully human Activin A-neutralizing antibody is the second approved medicine for…
